25 XP   0   0   10

Denali Therapeutics Inc
Buy, Hold or Sell?

Let's analyse Denali Therapeutics Inc together

PenkeI guess you are interested in Denali Therapeutics Inc. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Denali Therapeutics Inc. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Denali Therapeutics Inc

I send you an email if I find something interesting about Denali Therapeutics Inc.

Quick analysis of Denali Therapeutics Inc (30 sec.)










What can you expect buying and holding a share of Denali Therapeutics Inc? (30 sec.)

How much money do you get?

How much money do you get?
€0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
€6.92
Expected worth in 1 year
€6.85
How sure are you?
33.3%

+ What do you gain per year?

Total Gains per Share
€-0.08
Return On Investment
-0.5%

For what price can you sell your share?

Current Price per Share
€14.36
Expected price per share
€0 - €19.41
How sure are you?
50%

1. Valuation of Denali Therapeutics Inc (5 min.)




Live pricePrice per Share (EOD)

€14.36

Intrinsic Value Per Share

€-206.25 - €-247.67

Total Value Per Share

€-199.33 - €-240.75

2. Growth of Denali Therapeutics Inc (5 min.)




Is Denali Therapeutics Inc growing?

Current yearPrevious yearGrowGrow %
How rich?$1b$914m$161.6m15.0%

How much money is Denali Therapeutics Inc making?

Current yearPrevious yearGrowGrow %
Making money-$36.3m-$81.4m$45.1m124.5%
Net Profit Margin-2,022.9%-1,032.2%--

How much money comes from the company's main activities?

3. Financial Health of Denali Therapeutics Inc (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#55 / 1010

Most Revenue
#110 / 1010

Most Profit
#837 / 1010

Most Efficient
#848 / 1010

What can you expect buying and holding a share of Denali Therapeutics Inc? (5 min.)

Welcome investor! Denali Therapeutics Inc's management wants to use your money to grow the business. In return you get a share of Denali Therapeutics Inc.

What can you expect buying and holding a share of Denali Therapeutics Inc?

First you should know what it really means to hold a share of Denali Therapeutics Inc. And how you can make/lose money.

Speculation

The Price per Share of Denali Therapeutics Inc is €14.36. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Denali Therapeutics Inc.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Denali Therapeutics Inc, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is €6.92. Based on the TTM, the Book Value Change Per Share is €-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is €0.13 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is €0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Denali Therapeutics Inc.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps-0.86-6.0%-0.26-1.8%-0.59-4.1%-0.32-2.2%-0.32-2.2%
Usd Book Value Change Per Share-0.63-4.4%-0.02-0.1%0.141.0%0.412.9%0.412.9%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.63-4.4%-0.02-0.1%0.141.0%0.412.9%0.412.9%
Usd Price Per Share21.48-23.40-30.46-33.50-33.50-
Price to Earnings Ratio-6.25--3.79--13.76--12.76--12.76-
Price-to-Total Gains Ratio-34.21--24.87--66.48--60.68--60.68-
Price to Book Ratio2.90-3.02-4.70-5.26-5.26-
Price-to-Total Gains Ratio-34.21--24.87--66.48--60.68--60.68-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share15.362721
Number of shares65
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.020.41
Usd Total Gains Per Share-0.020.41
Gains per Quarter (65 shares)-1.3426.75
Gains per Year (65 shares)-5.36107.01
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-5-15010797
20-11-200214204
30-16-250321311
40-21-300428418
50-27-350535525
60-32-400642632
70-38-450749739
80-43-500856846
90-48-550963953
100-54-60010701060

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.03.00.025.0%1.011.00.08.3%2.016.00.011.1%2.016.00.011.1%2.016.00.011.1%
Book Value Change Per Share1.03.00.025.0%2.010.00.016.7%6.012.00.033.3%6.012.00.033.3%6.012.00.033.3%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.018.00.0%0.00.018.00.0%0.00.018.00.0%
Total Gains per Share1.03.00.025.0%2.010.00.016.7%6.012.00.033.3%6.012.00.033.3%6.012.00.033.3%

Fundamentals of Denali Therapeutics Inc

About Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Fundamental data was last updated by Penke on 2024-04-18 05:04:06.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is fair priced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Denali Therapeutics Inc.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Denali Therapeutics Inc earns for each €1 of revenue.

  • Above 10% is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • A Net Profit Margin of 0.0% means that €0.00 for each €1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Denali Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-2,022.9%+2,022.9%
TTM-2,022.9%YOY-1,032.2%-990.7%
TTM-2,022.9%5Y-1,121.7%-901.2%
5Y-1,121.7%10Y-1,121.7%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--207.2%+207.2%
TTM-2,022.9%-216.8%-1,806.1%
YOY-1,032.2%-282.3%-749.9%
5Y-1,121.7%-436.8%-684.9%
10Y-1,121.7%-597.3%-524.4%
1.1.2. Return on Assets

Shows how efficient Denali Therapeutics Inc is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • -10.4% Return on Assets means that Denali Therapeutics Inc generated €-0.10 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Denali Therapeutics Inc:

  • The MRQ is -10.4%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -3.0%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-10.4%TTM-3.0%-7.3%
TTM-3.0%YOY-6.2%+3.1%
TTM-3.0%5Y-4.5%+1.5%
5Y-4.5%10Y-4.5%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-10.4%-13.3%+2.9%
TTM-3.0%-12.8%+9.8%
YOY-6.2%-11.6%+5.4%
5Y-4.5%-13.8%+9.3%
10Y-4.5%-15.6%+11.1%
1.1.3. Return on Equity

Shows how efficient Denali Therapeutics Inc is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • -11.6% Return on Equity means Denali Therapeutics Inc generated €-0.12 for each €1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Denali Therapeutics Inc:

  • The MRQ is -11.6%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -4.1%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-11.6%TTM-4.1%-7.5%
TTM-4.1%YOY-9.0%+4.9%
TTM-4.1%5Y-6.2%+2.1%
5Y-6.2%10Y-6.2%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-11.6%-16.9%+5.3%
TTM-4.1%-16.1%+12.0%
YOY-9.0%-14.9%+5.9%
5Y-6.2%-19.3%+13.1%
10Y-6.2%-20.1%+13.9%

1.2. Operating Efficiency of Denali Therapeutics Inc.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Denali Therapeutics Inc is operating .

  • Measures how much profit Denali Therapeutics Inc makes for each €1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • An Operating Margin of 0.0% means the company generated €0.00  for each €1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Denali Therapeutics Inc:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-71.5%+71.5%
TTM-71.5%YOY-1,079.8%+1,008.4%
TTM-71.5%5Y-707.6%+636.1%
5Y-707.6%10Y-707.6%0.0%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ--298.0%+298.0%
TTM-71.5%-238.5%+167.0%
YOY-1,079.8%-288.4%-791.4%
5Y-707.6%-486.2%-221.4%
10Y-707.6%-628.4%-79.2%
1.2.2. Operating Ratio

Measures how efficient Denali Therapeutics Inc is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 0.00 means that the operating costs are €0.00 for each €1 in net sales.

Let's take a look of the Operating Ratio trends of Denali Therapeutics Inc:

  • The MRQ is 0.000. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM23.918-23.918
TTM23.918YOY11.798+12.120
TTM23.9185Y13.095+10.823
5Y13.09510Y13.0950.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-3.235-3.235
TTM23.9183.310+20.608
YOY11.7983.838+7.960
5Y13.0955.679+7.416
10Y13.0957.823+5.272

1.3. Liquidity of Denali Therapeutics Inc.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Denali Therapeutics Inc is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 13.65 means the company has €13.65 in assets for each €1 in short-term debts.

Let's take a look of the Current Ratio trends of Denali Therapeutics Inc:

  • The MRQ is 13.646. The company is very able to pay all its short-term debts. +2
  • The TTM is 12.685. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ13.646TTM12.685+0.961
TTM12.685YOY3.256+9.428
TTM12.6855Y11.684+1.001
5Y11.68410Y11.6840.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ13.6463.863+9.783
TTM12.6854.169+8.516
YOY3.2565.337-2.081
5Y11.6846.122+5.562
10Y11.6846.434+5.250
1.3.2. Quick Ratio

Measures if Denali Therapeutics Inc is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • A Quick Ratio of 11.68 means the company can pay off €11.68 for each €1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Denali Therapeutics Inc:

  • The MRQ is 11.680. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 10.906. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ11.680TTM10.906+0.774
TTM10.906YOY2.740+8.166
TTM10.9065Y8.473+2.433
5Y8.47310Y8.4730.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ11.6803.504+8.176
TTM10.9063.991+6.915
YOY2.7405.371-2.631
5Y8.4736.088+2.385
10Y8.4736.395+2.078

1.4. Solvency of Denali Therapeutics Inc.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Denali Therapeutics Inc assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Denali Therapeutics Inc to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Denali Therapeutics Inc assets are financed with 10.7% credit (debt) and the remaining percentage (100% - 10.7%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Denali Therapeutics Inc:

  • The MRQ is 0.107. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.152. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.107TTM0.152-0.045
TTM0.152YOY0.311-0.160
TTM0.1525Y0.250-0.098
5Y0.25010Y0.2500.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1070.339-0.232
TTM0.1520.337-0.185
YOY0.3110.271+0.040
5Y0.2500.368-0.118
10Y0.2500.388-0.138
1.4.2. Debt to Equity Ratio

Measures if Denali Therapeutics Inc is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • A Debt to Equity ratio of 11.9% means that company has €0.12 debt for each €1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Denali Therapeutics Inc:

  • The MRQ is 0.119. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.196. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.119TTM0.196-0.077
TTM0.196YOY0.454-0.258
TTM0.1965Y0.347-0.151
5Y0.34710Y0.3470.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1190.392-0.273
TTM0.1960.403-0.207
YOY0.4540.335+0.119
5Y0.3470.427-0.080
10Y0.3470.461-0.114

2. Market Valuation of Denali Therapeutics Inc

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every €1 in earnings Denali Therapeutics Inc generates.

  • Above 15 is considered overpriced but always compare Denali Therapeutics Inc to the Biotechnology industry mean.
  • A PE ratio of -6.25 means the investor is paying €-6.25 for every €1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Denali Therapeutics Inc:

  • The EOD is -4.474. Based on the earnings, the company is expensive. -2
  • The MRQ is -6.255. Based on the earnings, the company is expensive. -2
  • The TTM is -3.794. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-4.474MRQ-6.255+1.781
MRQ-6.255TTM-3.794-2.461
TTM-3.794YOY-13.760+9.966
TTM-3.7945Y-12.757+8.963
5Y-12.75710Y-12.7570.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-4.474-2.300-2.174
MRQ-6.255-2.656-3.599
TTM-3.794-2.718-1.076
YOY-13.760-4.145-9.615
5Y-12.757-6.258-6.499
10Y-12.757-6.315-6.442
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Denali Therapeutics Inc:

  • The EOD is -5.297. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -7.406. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -9.127. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-5.297MRQ-7.406+2.109
MRQ-7.406TTM-9.127+1.721
TTM-9.127YOY-16.874+7.747
TTM-9.1275Y-116.070+106.942
5Y-116.07010Y-116.0700.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-5.297-2.974-2.323
MRQ-7.406-3.306-4.100
TTM-9.127-3.508-5.619
YOY-16.874-5.613-11.261
5Y-116.070-8.378-107.692
10Y-116.070-8.873-107.197
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Denali Therapeutics Inc is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 2.90 means the investor is paying €2.90 for each €1 in book value.

Let's take a look of the Price to Book Ratio trends of Denali Therapeutics Inc:

  • The EOD is 2.074. Based on the equity, the company is underpriced. +1
  • The MRQ is 2.899. Based on the equity, the company is underpriced. +1
  • The TTM is 3.023. Based on the equity, the company is fair priced.
Trends
Current periodCompared to+/- 
EOD2.074MRQ2.899-0.826
MRQ2.899TTM3.023-0.124
TTM3.023YOY4.699-1.676
TTM3.0235Y5.258-2.235
5Y5.25810Y5.2580.000
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD2.0741.914+0.160
MRQ2.8992.116+0.783
TTM3.0232.097+0.926
YOY4.6992.881+1.818
5Y5.2583.550+1.708
10Y5.2583.936+1.322
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Denali Therapeutics Inc compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.587-0.019-97%0.135-536%0.385-253%0.385-253%
Book Value Per Share--6.9227.223-4%6.137+13%5.978+16%5.978+16%
Current Ratio--13.64612.685+8%3.256+319%11.684+17%11.684+17%
Debt To Asset Ratio--0.1070.152-30%0.311-66%0.250-57%0.250-57%
Debt To Equity Ratio--0.1190.196-39%0.454-74%0.347-66%0.347-66%
Dividend Per Share----0%-0%-0%-0%
Eps---0.802-0.244-70%-0.547-32%-0.295-63%-0.295-63%
Free Cash Flow Per Share---0.677-0.623-8%-0.441-35%-0.185-73%-0.185-73%
Free Cash Flow To Equity Per Share---0.646-0.593-8%0.081-900%0.228-384%0.228-384%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max---247.674--------
Intrinsic Value_10Y_min---206.250--------
Intrinsic Value_1Y_max---5.233--------
Intrinsic Value_1Y_min---5.129--------
Intrinsic Value_3Y_max---30.650--------
Intrinsic Value_3Y_min---28.960--------
Intrinsic Value_5Y_max---74.063--------
Intrinsic Value_5Y_min---67.459--------
Market Cap1997641800.000-40%2792941200.0003042211550.000-8%3960145700.000-29%4355468335.556-36%4355468335.556-36%
Net Profit Margin----20.2290%-10.3220%-11.2170%-11.2170%
Operating Margin----0.7150%-10.7980%-7.0760%-7.0760%
Operating Ratio---23.918-100%11.798-100%13.095-100%13.095-100%
Pb Ratio2.074-40%2.8993.023-4%4.699-38%5.258-45%5.258-45%
Pe Ratio-4.474+28%-6.255-3.794-39%-13.760+120%-12.757+104%-12.757+104%
Price Per Share14.355-40%20.07021.861-8%28.458-29%31.298-36%31.298-36%
Price To Free Cash Flow Ratio-5.297+28%-7.406-9.127+23%-16.874+128%-116.070+1467%-116.070+1467%
Price To Total Gains Ratio-24.467+28%-34.208-24.872-27%-66.476+94%-60.677+77%-60.677+77%
Quick Ratio--11.68010.906+7%2.740+326%8.473+38%8.473+38%
Return On Assets---0.104-0.030-71%-0.062-40%-0.045-56%-0.045-56%
Return On Equity---0.116-0.041-65%-0.090-22%-0.062-46%-0.062-46%
Total Gains Per Share---0.587-0.019-97%0.135-536%0.385-253%0.385-253%
Usd Book Value--1030948721.5161075698492.396-4%914022320.182+13%890284108.389+16%890284108.389+16%
Usd Book Value Change Per Share---0.628-0.021-97%0.144-536%0.412-253%0.412-253%
Usd Book Value Per Share--7.4087.730-4%6.568+13%6.398+16%6.398+16%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.859-0.261-70%-0.586-32%-0.316-63%-0.316-63%
Usd Free Cash Flow---100891483.433-92732025.210-8%-65636913.937-35%-24461596.978-76%-24461596.978-76%
Usd Free Cash Flow Per Share---0.725-0.666-8%-0.472-35%-0.198-73%-0.198-73%
Usd Free Cash Flow To Equity Per Share---0.691-0.634-8%0.086-900%0.244-384%0.244-384%
Usd Market Cap2137876254.360-40%2989005672.2403255774800.810-8%4238147928.140-29%4661222212.712-36%4661222212.712-36%
Usd Price Per Share15.363-40%21.47923.396-8%30.455-29%33.495-36%33.495-36%
Usd Profit---119472388.298-36305814.113-70%-81497332.732-32%-43941163.909-63%-43941163.909-63%
Usd Revenue---82632326.920-100%27115611.167-100%46754760.614-100%46754760.614-100%
Usd Total Gains Per Share---0.628-0.021-97%0.144-536%0.412-253%0.412-253%
 EOD+3 -5MRQTTM+8 -23YOY+11 -205Y+11 -2010Y+11 -20

3.2. Fundamental Score

Let's check the fundamental score of Denali Therapeutics Inc based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-4.474
Price to Book Ratio (EOD)Between0-12.074
Net Profit Margin (MRQ)Greater than00.000
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than111.680
Current Ratio (MRQ)Greater than113.646
Debt to Asset Ratio (MRQ)Less than10.107
Debt to Equity Ratio (MRQ)Less than10.119
Return on Equity (MRQ)Greater than0.15-0.116
Return on Assets (MRQ)Greater than0.05-0.104
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Denali Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.944
Ma 20Greater thanMa 5016.836
Ma 50Greater thanMa 10017.439
Ma 100Greater thanMa 20017.373
OpenGreater thanClose14.355
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in USD. All numbers in thousands.

Summary
Total Assets1,153,917
Total Liabilities122,963
Total Stockholder Equity1,030,954
 As reported
Total Liabilities 122,963
Total Stockholder Equity+ 1,030,954
Total Assets = 1,153,917

Assets

Total Assets1,153,917
Total Current Assets1,064,137
Long-term Assets89,780
Total Current Assets
Cash And Cash Equivalents 127,106
Short-term Investments 907,405
Net Receivables 3,420
Total Current Assets  (as reported)1,064,137
Total Current Assets  (calculated)1,037,931
+/- 26,206
Long-term Assets
Property Plant Equipment 71,637
Long-term Assets Other 18,143
Long-term Assets  (as reported)89,780
Long-term Assets  (calculated)89,780
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities77,982
Long-term Liabilities44,981
Total Stockholder Equity1,030,954
Total Current Liabilities
Accounts payable 9,483
Total Current Liabilities  (as reported)77,982
Total Current Liabilities  (calculated)9,483
+/- 68,499
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt52,241
Long-term Liabilities  (as reported)44,981
Long-term Liabilities  (calculated)52,241
+/- 7,260
Total Stockholder Equity
Total Stockholder Equity (as reported)1,030,954
Total Stockholder Equity (calculated)0
+/- 1,030,954
Other
Capital Stock1,711
Common Stock Shares Outstanding 138,197
Net Invested Capital 1,030,954
Net Working Capital 986,155
Property Plant and Equipment Gross 117,640



Balance Sheet

Currency in USD. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-30
> Total Assets 
602,978
553,231
695,865
647,337
1,070,306
1,604,280
1,547,858
1,509,815
1,449,966
1,404,162
1,320,858
1,292,462
1,227,606
1,460,242
1,409,344
1,305,734
1,236,777
1,153,917
1,153,9171,236,7771,305,7341,409,3441,460,2421,227,6061,292,4621,320,8581,404,1621,449,9661,509,8151,547,8581,604,2801,070,306647,337695,865553,231602,978
   > Total Current Assets 
494,377
430,031
604,785
559,409
970,866
1,495,655
1,431,622
1,341,745
1,055,509
897,234
988,436
1,114,600
1,138,526
1,372,319
1,325,162
1,224,062
1,142,884
1,064,137
1,064,1371,142,8841,224,0621,325,1621,372,3191,138,5261,114,600988,436897,2341,055,5091,341,7451,431,6221,495,655970,866559,409604,785430,031494,377
       Cash And Cash Equivalents 
82,673
79,449
207,537
137,184
351,047
507,144
435,321
485,680
394,553
293,477
104,953
155,088
118,615
218,044
68,131
131,973
148,011
127,106
127,106148,011131,97368,131218,044118,615155,088104,953293,477394,553485,680435,321507,144351,047137,184207,53779,44982,673
       Short-term Investments 
396,717
335,907
379,713
412,397
610,154
962,553
977,827
823,251
644,622
571,930
852,569
913,580
987,440
1,118,171
1,220,322
1,059,014
961,245
907,405
907,405961,2451,059,0141,220,3221,118,171987,440913,580852,569571,930644,622823,251977,827962,553610,154412,397379,713335,907396,717
       Net Receivables 
0
0
0
0
0
5,674
2,511
16,785
1,194
1,226
0
357
0
9,282
0
3,400
0
3,420
3,42003,40009,282035701,2261,19416,7852,5115,67400000
       Other Current Assets 
0
0
0
0
0
200
0
0
0
0
30,914
45,575
32,471
36,104
36,709
33,075
33,628
0
033,62833,07536,70936,10432,47145,57530,914000020000000
   > Long-term Assets 
108,601
123,200
91,080
87,928
99,440
108,625
116,236
168,070
394,457
506,928
332,422
177,862
89,080
87,923
84,182
81,672
93,893
89,780
89,78093,89381,67284,18287,92389,080177,862332,422506,928394,457168,070116,236108,62599,44087,92891,080123,200108,601
       Property Plant Equipment 
81,825
80,655
79,078
76,934
75,241
73,464
73,612
71,972
71,208
69,608
67,942
68,458
72,963
74,524
70,166
67,238
74,851
71,637
71,63774,85167,23870,16674,52472,96368,45867,94269,60871,20871,97273,61273,46475,24176,93479,07880,65581,825
       Long Term Investments 
23,534
39,886
9,684
7,229
20,341
32,699
38,885
92,522
319,472
425,449
250,268
94,220
0
0
0
0
7,905
0
07,905000094,220250,268425,449319,47292,52238,88532,69920,3417,2299,68439,88623,534
       Other Assets 
3,242
2,659
2,318
3,765
3,858
2,462
3,739
3,576
3,777
11,871
14,212
15,184
16,117
13,399
14,016
14,434
0
0
0014,43414,01613,39916,11715,18414,21211,8713,7773,5763,7392,4623,8583,7652,3182,6593,242
> Total Liabilities 
164,781
158,341
150,554
145,170
187,756
453,749
442,505
437,110
437,689
441,871
402,931
408,014
416,303
417,812
442,638
118,909
118,446
122,963
122,963118,446118,909442,638417,812416,303408,014402,931441,871437,689437,110442,505453,749187,756145,170150,554158,341164,781
   > Total Current Liabilities 
46,685
45,344
47,635
58,464
105,413
71,699
54,610
51,412
54,251
378,245
341,240
348,160
360,670
363,922
391,080
69,357
71,180
77,982
77,98271,18069,357391,080363,922360,670348,160341,240378,24554,25151,41254,61071,699105,41358,46447,63545,34446,685
       Accounts payable 
2,022
2,590
2,316
1,866
2,806
1,071
1,626
4,235
4,817
4,779
3,358
7,116
7,539
2,790
2,215
8,520
1,182
9,483
9,4831,1828,5202,2152,7907,5397,1163,3584,7794,8174,2351,6261,0712,8061,8662,3162,5902,022
       Other Current Liabilities 
3,483
18,747
24,674
34,134
72,869
23,483
16,455
9,193
4,762
320,301
293,340
290,424
291,982
294,441
298,295
7,821
0
0
007,821298,295294,441291,982290,424293,340320,3014,7629,19316,45523,48372,86934,13424,67418,7473,483
   > Long-term Liabilities 
118,096
112,997
102,919
86,706
82,343
382,050
387,895
385,698
383,438
63,626
61,691
59,854
55,633
53,890
51,558
49,552
47,266
44,981
44,98147,26649,55251,55853,89055,63359,85461,69163,626383,438385,698387,895382,05082,34386,706102,919112,997118,096
       Capital Lease Obligations Min Short Term Debt
69,915
72,530
71,914
70,942
69,915
68,865
67,792
66,451
65,242
58,554
62,745
61,396
62,046
53,032
57,085
55,525
53,901
52,241
52,24153,90155,52557,08553,03262,04661,39662,74558,55465,24266,45167,79268,86569,91570,94271,91472,53069,915
       Other Liabilities 
48,181
44,132
35,126
20,094
16,936
317,875
324,979
324,302
323,448
5,072
4,605
4,329
655
858
1,012
801
0
0
008011,0128586554,3294,6055,072323,448324,302324,979317,87516,93620,09435,12644,13248,181
> Total Stockholder Equity
438,197
394,890
545,311
502,167
882,550
1,150,531
1,105,353
1,072,705
1,012,277
962,291
917,927
884,448
811,303
1,042,430
966,706
1,186,825
1,118,331
1,030,954
1,030,9541,118,3311,186,825966,7061,042,430811,303884,448917,927962,2911,012,2771,072,7051,105,3531,150,531882,550502,167545,311394,890438,197
   Common Stock
1,286
1,288
1,382
1,385
1,524
1,531
1,537
1,541
1,545
1,548
1,554
1,558
1,564
1,686
1,694
1,700
0
0
001,7001,6941,6861,5641,5581,5541,5481,5451,5411,5371,5311,5241,3851,3821,2881,286
   Retained Earnings Total Equity000000000000000000
   Accumulated Other Comprehensive Income 000000000000000000
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000
   Other Stockholders Equity 
562
350
835
551
11
-245
-232
-368
-521
-2,499
-9,251
-12,274
-11,853
-6,886
-2,517
-1,441
0
0
00-1,441-2,517-6,886-11,853-12,274-9,251-2,499-521-368-232-24511551835350562



Balance Sheet

Currency in USD. All numbers in thousands.




Cash Flow

Currency in USD. All numbers in thousands.




Income Statement

Currency in USD. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue330,531
Cost of Revenue--
Gross Profit-330,531
 
Operating Income (+$)
Gross Profit-
Operating Expense-527,230
Operating Income-196,699-527,230
 
Operating Expense (+$)
Research Development423,876
Selling General Administrative103,354
Selling And Marketing Expenses-
Operating Expense527,230527,230
 
Net Interest Income (+$)
Interest Income51,505
Interest Expense--
Other Finance Cost-0
Net Interest Income51,505
 
Pretax Income (+$)
Operating Income-196,699
Net Interest Income51,505
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-145,194-196,699
EBIT - interestExpense = 0
-145,224
-145,224
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--145,194
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-145,194
Tax Provision-30
Net Income From Continuing Ops-145,224-145,224
Net Income-145,224
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net--51,505
 

Technical Analysis of Denali Therapeutics Inc
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Denali Therapeutics Inc. The general trend of Denali Therapeutics Inc is BEARISH with 85.7% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Denali Therapeutics Inc's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-85.7%) Bearish trend (85.7%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Denali Therapeutics Inc.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 14.64 < 16.91 < 19.41.

The bearish price targets are: .

Tweet this
Denali Therapeutics Inc Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Denali Therapeutics Inc. The current mas is .

The long score for the Moving Averages is 1/14.
The longshort score for the Moving Averages is -12/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 > MA 100: The MA 50 is higher than the MA 100. +1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Denali Therapeutics Inc Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Denali Therapeutics Inc. The current macd is -0.85882449.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Denali Therapeutics Inc price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Denali Therapeutics Inc. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Denali Therapeutics Inc price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
Denali Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) ChartDenali Therapeutics Inc Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Denali Therapeutics Inc. The current adx is 20.36.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Denali Therapeutics Inc shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Denali Therapeutics Inc Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Denali Therapeutics Inc. The current sar is 17.64.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Denali Therapeutics Inc Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Denali Therapeutics Inc. The current rsi is 31.94. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
Denali Therapeutics Inc Daily Relative Strength Index (RSI) ChartDenali Therapeutics Inc Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Denali Therapeutics Inc. The current phase is Oversold in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -6/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH < 20: The STOCH %K is below 20 and oversold. -2
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Denali Therapeutics Inc price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Denali Therapeutics Inc Daily Stochastic Oscillator ChartDenali Therapeutics Inc Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Denali Therapeutics Inc. The current cci is -143.78518839.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Denali Therapeutics Inc Daily Commodity Channel Index (CCI) ChartDenali Therapeutics Inc Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Denali Therapeutics Inc. The current cmo is -51.47589402.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Denali Therapeutics Inc Daily Chande Momentum Oscillator (CMO) ChartDenali Therapeutics Inc Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Denali Therapeutics Inc. The current willr is -100.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is -1/(-1 +1).

  • WILLR < -80: The Williams %R is below -80. This indicates that the price is in oversold territory, suggesting a potential price correction or trend reversal to the upside. -1
Denali Therapeutics Inc Daily Williams %R ChartDenali Therapeutics Inc Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Denali Therapeutics Inc.

Denali Therapeutics Inc Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Denali Therapeutics Inc. The current atr is 0.50830519.

Denali Therapeutics Inc Daily Average True Range (ATR) ChartDenali Therapeutics Inc Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Denali Therapeutics Inc. The current obv is 5,408.

Denali Therapeutics Inc Daily On-Balance Volume (OBV) ChartDenali Therapeutics Inc Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Denali Therapeutics Inc. The current mfi is 29.97.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Denali Therapeutics Inc Daily Money Flow Index (MFI) ChartDenali Therapeutics Inc Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Denali Therapeutics Inc.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-12-04 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-05 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-08 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-11 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-12-13 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-14 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-12-19 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-20 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-21 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-27 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-02 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-03 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-04 00:00:00WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-05 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-09 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-10 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-11 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-19 00:00:00ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-22 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-23 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-24 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-25 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-30 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-31 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-05 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-07 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08 00:00:00MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
2024-02-09 00:00:00SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-12 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-13 00:00:00BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-14 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-15 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-16 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-19 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-20 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-22 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-28 00:00:00DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29 00:00:00RSI SHORT ENTRY LONG CLOSE70 crossover to downside
STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-04 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-06 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-08 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-13 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15 00:00:00CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-18 00:00:00MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-19 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21 00:00:00WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-03-27 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-03-28 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-03 00:00:00DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-04 00:00:00SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-05 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-08 00:00:00ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-09 00:00:00CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-11 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-12 00:00:00STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-15 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17 00:00:00MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18 00:00:00BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-22 00:00:00MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-25 00:00:00STOCH LONG EXITThe %K line crosses below the %D line.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).

6.3. Candlestick Patterns

Denali Therapeutics Inc Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Denali Therapeutics Inc based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5031.944
Ma 20Greater thanMa 5016.836
Ma 50Greater thanMa 10017.439
Ma 100Greater thanMa 20017.373
OpenGreater thanClose14.355
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Denali Therapeutics Inc with someone you think should read this too:
  • Are you bullish or bearish on Denali Therapeutics Inc? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Denali Therapeutics Inc? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Denali Therapeutics Inc

I send you an email if I find something interesting about Denali Therapeutics Inc.


Comments

How you think about this?

Leave a comment

Stay informed about Denali Therapeutics Inc.

Receive notifications about Denali Therapeutics Inc in your mailbox!